Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor

Cancer Letters

Volumn 345, Issue 1, 2014, Pages 56-64

  Seol, Hyang Sook ^a   Kang, HyoJeong ^a   Lee, Seul I ^a   Kim, Na Eun ^a   Kim, Tae Im ^a   Chun, Sung Min ^a   Kim, Tae Won ^a   Yu, Chang sik ^a   Suh, Young Ah ^a   Singh, Shree Ram ^b   Chang, Suhwan ^a   Jang, Se Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Colon cancer; Drug sensitivity; Oncomap analysis; Patient derived xenograft (PDX); Primary culture

Indexed keywords

COLON CANCER; DRUG SENSITIVITY; ONCOMAP ANALYSIS; PATIENT DERIVED XENOGRAFT (PDX); PRIMARY CULTURE;

ADULT; AGED; ANIMALS; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENOTYPE; HUMANS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; MUTATION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84893753547     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.11.010     Document Type: Article

References (38)

1. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe. Eur. J. Cancer 2008, 46(2010):765-781.
2. American Cancer Society Colorectal Cancer Facts & Figures 2011-2013 2011, American Cancer Society, Atlanta, GA.
3. Bustin S.A., Murphy J. RNA biomarkers in colorectal cancer. Methods 2013, 59:116-125.
4. Chung H.H., Jang B.I. A perspective: role of targeted therapy in colon cancer. Korean J. Gastroenterol. 2013, 61:128-135.
5. Francescangeli F., Patrizii M., Signore M., Federici G., Di Franco S., Pagliuca A., Baiocchi M., Biffoni M., Ricci Vitiani L., Todaro M., De Maria R., Zeuner A. Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. Stem Cells 2012, 30:1819-1830.
6. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Eng. J. Med. 2004, 350:2335-2342.
7. Van Cutsem E., Köhne C.H., Hitre E., Zaluski J., Chang Chien C.R., Makhson A., D'Haens G., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
8. Douillard J.Y., Siena S., Cassidy J., Tabernero J., Burkes R., Barugel M., Humblet Y., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010, 28:4697-4705.
9. Hagan S., Orr M.C., Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J. 2013, 4:3.
10. Dotan E., Goldstein L.J. Optimizing chemotherapy regimens for patients with early-stage breast cancer. Clin. Breast Cancer 2010, 10(Suppl 1):E8-15.
11. Johnson K.A., Brown P.H. Drug development for cancer chemoprevention: focus on molecular targets. Semin. Oncol. 2010, 37:345-358.
12. Azzoli C.G., Park B.J., Pao W., Zakowski M., Kris M.G. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J. Thoracic Oncol. 2008, 3:84-93.
13. Hao Y., Wang C., Cao B., Hirsch B.M., Song J., Markowitz S.D., Ewing R.M., Sedwick D., Liu L., Zheng W., Wang Z. Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions. Cancer Cell 2013, 23:583-593.
14. Herbst R.S., Heymach J.V., Lippman S.M. Lung cancer. N. Engl. J. Med. 2008, 359:1367-1380.
15. De Witt Hamer P.C., Van Tilborg A.A., Eijk P.P., Sminia P., Troost D., Van Noorden C.J., Ylstra B., Leenstra S. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008, 27:2091-2096.
16. Pandita A., Aldape K.D., Zadeh G., Guha A., James C.D. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004, 39:29-36.
17. Jass J.R. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007, 50:113-130.
18. John T., Kohler D., Pintilie M., Yanagawa N., Pham N.A., Li M., Panchal D., Hui F., Meng F., Shepherd F.A., Tsao M.S. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer. Clin. Cancer Res.: Official J. Am. Assoc. Cancer Res. 2011, 17:134-141.
19. Julien S., Merino-Trigo A., Lacroix L., Pocard M., Goere D., Mariani P., Landron S., Bigot L., Nemati F., Dartigues P., Weiswald L.B., Lantuas D., Morgand L., Pham E., Gonin P., Dangles-Marie V., Job B., Dessen P., Bruno A., Pierre A., De The H., Soliman H., Nunes M., Lardier G., Calvet L., Demers B., Prevost G., Vrignaud P., Roman-Roman S., Duchamp O., Berthet C. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin. Cancer Res. 2012, 18:5314-5328.
20. Jin K., Lan H., Cao F., Han N., Xu Z., Li G., He K., Teng L. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases. Int. J. Oncol. 2012, 41:583-588.
21. Dong X., Jin K., Hu X., Du F., Lan H., Han N., Ma Z., Xie B., Cui B., Teng L., Cao F. Antitumor effect of FP3 in combination with cetuximab on patient-derived tumor tissue xenograft models of primary colon carcinoma and related lymphatic and hepatic metastases. Int. J. Mol. Med. 2012, 30:126-132.
22. Siolas D., Hannon G.J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 2013, 73:5315-5319.
23. Dong X., Guan J., English J.C., Flint J., Yee J., Evans K., Murray N., Macaulay C., Ng R.T., Gout P.W., Lam W.L., Laskin J., Ling V., Lam S., Wang Y. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy. Clin. Cancer Res. 2010, 16:1442-1451.
24. Laurent C., Gentien D., Piperno-Neumann S., Némati F., Nicolas A., Tesson B., Desjardins L., Mariani P., Rapinat A., Sastre-Garau X., Couturier J., Hupé P., de Koning L., Dubois T., Roman-Roman S., Stern M.H., Barillot E., Harbour J.W., Saule S., Decaudin D. Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol. Oncol. 2013, 7:625-636.
25. Kopetz S., Lemos R., Powis G. The promise of patient-derived xenografts: the best laid plans of mice and men. Clin. Cancer Res. 2012, 18:5160-5162.
26. Chaudary N., Pintilie M., Schwock J., Dhani N., Clarke B., Milosevic M., Fyles A., Hill R.P. Characterization of the tumor-microenvironment in patient-derived cervix xenografts (OCICx). Cancers (Basel) 2012, 4:821-845.
27. John T., Yanagawa N., Kohler D., Craddock K.J., Bandarchi-Chamkhaleh B., Pintilie M., Sykes J., To C., Li M., Panchal D., Chen W., Shepherd F.A., Tsao M.S. Characterization of lymphomas developing in immunodeficient mice implanted with primary human non-small cell lung cancer. J. Thoracic Oncol. 2012, 7:1101-1108.
28. MacConaill L.E., Campbell C.D., Kehoe S.M., Bass A.J., Hatton C., Niu L., Davis M., Yao K., Hanna M., Mondal C., Luongo L., Emery C.M., Baker A.C., Philips J., Goff D.J., Fiorentino M., Rubin M.A., Polyak K., Chan J., Wang Y., Fletcher J.A., Santagata S., Corso G., Roviello F., Shivdasani R., Kieran M.W., Ligon K.L., Stiles C.D., Hahn W.C., Meyerson M.L., Garraway L.A. Profiling critical cancer gene mutations in clinical tumor samples. PLoS ONE 2009, 4:e7887.
29. Zhang X.C., Zhang J., Li M., Huang X.S., Yang X.N., et al. Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies. J. Transl. Med. 2013, 11:168.
30. Landis M.D., Lehmann B.D., Pietenpol J.A., Chang J.C. Patient-derived breast tumor xenografts facilitating personalized cancer therapy. Breast Cancer Res. 2013, 15:201.
31. Seol H.S., Suh Y.A., Ryu Y.J., Kim H.J., Chun S.M., et al. A patient-derived xenograft mouse model generated from primary cultured cells recapitulates patient tumors phenotypically and genetically. J. Cancer Res. Clin. Oncol. 2013, 139:1471-1480.
32. Bertotti A., Migliardi G., Galimi F., Sassi F., Torti D., Isella C., Corà D., et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011, 1:508-523.
33. Krumbach R., Schüler J., Hofmann M., Giesemann T., Fiebig H.-H., Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur. J. Cancer 2011, 47:1231-1243.
34. Moro M., Bertolini G., Tortoreto M., Pastorino U., Sozzi G., Roz L. Patient-derived xenografts of non-small cell lung cancer: resurgence of an old model for investigation of modern concepts of tailored therapy and cancer stem cells. J. Biomed. Biotechnol. 2012, 567-568.
35. Fu Y., Besterman J.M., Monosov A., Hoffman R.M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc. Nat. Acad. Sci. USA 1991, 88:9345-9349.
36. Thalheimer A., Illert B., Bueter M., Gattenlohner S., Stehle D., Gasser M., Thiede A., Waaga-Gasser A.M., Meyer D. Feasibility and limits of an orthotopic human colon cancer model in nude mice. Comp. Med. 2006, 56:105-109.
37. Adiseshaiah P.P., Clogston J.D., McLeland C.B., Rodriguez J., Potter T.M., et al. Synergistic combination therapy with nanoliposomal C6-ceramide and vinblastine is associated with autophagy dysfunction in hepatocarcinoma and colorectal cancer models. Cancer Lett. 2013, 337:254-265.
38. Flis S., Spłwiński J. Inhibitory effects of 5-fluorouracil and oxaliplatin on human colorectal cancer cell survival are synergistically enhanced by sulindac sulfide. Anticancer Res. 2009, 29:435-441.